✦ LIBER ✦

Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma

✍ Scribed by F. C. Schell; H. Y. Yap; G. N. Hortobagyi; B. Issell; L. Esparza

Publisher: Springer
Year: 1982
Tongue: English
Weight: 302 KB
Volume: 7
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00254555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of VP 16-213 (etoposide)

Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer

✍ B. A. J. Ponder; R. T. D. Oliver 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 227 KB

Phase II study of paclitaxel in patients

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

✍ Edgardo Rivera; Frankie A. Holmes; Debra Frye; Vicente Valero; Richard L. Theria 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 3 views

Cisplatin, VP-16-213 and MGBG (Methylgly

Cisplatin, VP-16-213 and MGBG (Methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study

✍ Lyubica Dabich; Marcia K. Liepman 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 492 KB

In an effort to improve the treatment of patients with refractory or recurrent lymphoma, we developed a protocol using cis-platinum combined with two other agents of known efficacy in these disorders but with differing side effects: VP-16 and MGBG. Twenty-six eligible patients were treated with this

Phase II study of oral VP-16-213 in smal

Phase II study of oral VP-16-213 in small cell lung cancer

✍ Yasaku Matsui; Shunsaku Oshima; Masao Kado; Masahiko Nakayama; Kaoru Shimokata; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 1 views

Phase I study of VP-16 (etoposide) and a

Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia

✍ Letendre, Louis ;Hinemann, Vicky ;Hoagland, H. Clark ;Kovach, John S. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

Fourteen patients with refractory acute nonlymphocytic leukemia were entered into a doseseeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. There were three complete responses lasting 2 months, 3 months, and 10 months and two transient partial rem

Phase II trial of tamoxifen, etoposide,

Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma

✍ Suzanne D. Conzen; Peter A. Kaufman; Christine Arvizu; Paul LeMarbre; L. Herbert 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 554 KB

## BACKGROUND. Based on previous data demonstrating a potentially synergistic interaction between tamoxifen and cisplatin in metastatic melanoma therapy, a Phase I1 study was performed to assess the activity of tamoxifen, etoposide, mitoxantrone, and cisplatin (TEMP) in patients with metastatic br